Experimental cancer pill shows promise in early trial
NCT ID NCT03114319
First seen Apr 22, 2026 · Last updated May 14, 2026 · Updated 3 times
Summary
This early-stage study tested an experimental oral drug called TNO155 in 227 adults with advanced solid tumors (like lung, skin, or esophageal cancer) that had stopped responding to standard treatments. The main goal was to find safe doses and understand side effects, both when given alone and with another drug. The study was terminated early, but the results help guide future research on this type of targeted therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Center
Boston, Massachusetts, 02215, United States
-
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Memorial Sloane Ketterin Cancer Ctr
New York, New York, 10065, United States
-
Novartis Investigative Site
Toronto, Ontario, M5G 2M9, Canada
-
Novartis Investigative Site
Milan, MI, 20141, Italy
-
Novartis Investigative Site
Kobe, 650-0017, Japan
-
Novartis Investigative Site
Rotterdam, South Holland, 3015 GD, Netherlands
-
Novartis Investigative Site
Amsterdam, 1066 CX, Netherlands
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 05505, South Korea
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Madrid, 28040, Spain
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37221, United States
Conditions
Explore the condition pages connected to this study.